LONG-TERM OUTCOMES OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE - THE SWEDISH PROSPECTIVE MULTICENTRE SVEAH EXTENSION STUDY

Isabella Visuri  ¹     Carl Eriksson  ¹     Sara Karlqvist  ¹     VYRON LYKIARDOPOULOS  ²     Per Karlén  ³     Olof Grip  ⁴     Charlotte Söderman  ⁵     Sven Almer  ⁶     Erik Hertervig  ⁶     Jan Marsal  ⁶     Carolina Malmgren  ⁷     Jenny Delin  ⁸     Hans Strid  ⁹     Mats Sjöberg  ¹⁰     Daniel Bergemalm  ¹⁰     Henrik Hjortswang  ¹⁰     Jonas Halfvarson  ^10    
1 Örebro University, Örebro, Sweden
² Linköping University, Linköping, Sweden
³ Danderyd Hospital, Stockholm, Sweden
⁴ Skåne University Hospital, Malmö/Lund, Sweden
⁵ Capio St Göran Hospital, Stockholm, Sweden
⁶ Karolinska Institutet, Stockholm, Sweden
⁷ Takeda Pharma A/B, Solna, Sweden
⁸ Ersta Hospital, Stockholm, Sweden
⁹ Södra Älvsborgs Hospital, Borås, Sweden
¹⁰ Skaraborgs Hospital, Lidköping, Sweden

Session
Epidemiology in GI disease (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)